AFP-L3: a new generation of tumor marker for hepatocellular carcinoma
Section snippets
Chronic hepatitis and hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has become a public health concern in recent years largely due to the worldwide epidemic of hepatitis B and hepatitis C. There is an estimated 1.25 million and 2.7 million individuals with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, respectively, in the United States [1]. Viral hepatitis in general, and chronic hepatitis C in particular, is the most common cause of chronic liver disease. There were 120,000 to 180,000 new cases of
α-Fetoprotein
Alpha-fetoprotein (AFP) has been used in clinical diagnosis for HCC. AFP is synthesized in large quantities during embryonic development by fetal yolk sac and by the liver [7]. AFP concentration decreases gradually after birth to <10 ng/ml in 12–18 months [7], [8]. AFP reappears in maternal serum during pregnancy. Pathologically, it is associated with HCC, gastric carcinoma, lung cancer, pancreatic and biliary tract cancer, and testicular carcinoma, etc. [8]. Although AFP can arise in many
Glycoforms of α-Fetoprotein
AFP is a glycoprotein with a single asparagine-linked complex-type carbohydrate chain on each molecule. Over the past decades, research have shown that total AFP is a collection of heterogeneous glycoproteins consisting of three different glycoforms. AFP from benign chronic liver diseases, such as chronic hepatitis and liver cirrhosis, and from HCC displayed differential affinities to lectin, Lens culinaris agglutinin (LCA). The total AFP can be separated into three subspecies, AFP-L1 to
Clinical significance of α-Fetoprotein glycoforms
Early diagnosis of HCC has been difficult, if not impossible, in a background of cirrhosis. Screening program exists in some hospitals in North America for chronic cirrhotic patients by abdominal ultrasonography and serum AFP [12], [13]. Early recognition of HCC is based on screening high-risk patients with long history of chronic liver disease. In prospective studies, the positive predictive value for HCC of serum AFP was 32% compared to 54% for abdominal ultrasonography [6], [14], [15].
Automated assay for AFP-L3
Laboratory assay for AFP-L3 used to be based on lectin affinity electrophoresis and Western blotting [27], [28]. These assays were tedious with long turnaround times. Recently, an automated assay for measuring the AFP-L3 has been developed and introduced for clinical use in Japan. The new automated method for measurement of AFP-L3 is an immunoassay based on the liquid phase binding of L3 subspecies of AFP with two specific monoclonal antibodies labeled with peroxidase and polysulfated tyrosine
Summary
Taken together, AFP-L3 is a new generation of tumor marker for measuring micro-heterogeneity in sugar chain in AFP for HCC. Its very high specificity is complementary to the total AFP assay, providing a cost-effective test useful for early tumor recognition, diagnosis, follow-up after treatment, and prognosis of HCC patients. Development of an automated assay has enabled testing in reference laboratories that have a high testing volume.
References (31)
- et al.
Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis
J. Hepatol.
(1999) - et al.
Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey
Am. J. Gastroenterol.
(1999) - et al.
A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients
Hepatology
(1995) - et al.
Usefulness of measurement of lens culinaris agglutinin-reactive fraction of α-Fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma
Am. J. Gastroenterol.
(1999) - et al.
Prognostic significance of lens culinaris agglutinin a-reactive α-Fetoprotein in small hepatocellular carcinomas
Gastroenterology
(1996) - et al.
Comparison of carbohydrate structures of serum of α-Fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis
Clin. Chim. Acta
(1996) - et al.
Establishment of assay kits for the detection of microheterogeneities of α-Fetoprotein using lectin-affinity electrophoresis
Clin. Chim. Acta
(1993) - et al.
Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody
J. Immunol. Methods
(1998) Chronic viral hepatitis in the United States
Increasing incidence and pretransplantation screening of hepatocellular carcinoma
Liver Transplant.
(2000)
Primary hepatocellular carcinoma
Risk factor for the rising rates of primary liver cancer in the United States
Arch. Intern. Med.
Rising incidence of hepatocellular carcinoma in the United States
N. Engl. J. Med.
Viral hepatitis and cancer
Tumor markers
Cited by (305)
A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2
2023, Journal of Biological ChemistryEnrichment driven glycoproteomics: New materials, new methods, and beyond
2023, TrAC - Trends in Analytical ChemistrySerum biomarkers and ultrasensitive biosensors for diagnosis of early-stage hepatocellular carcinoma
2023, Sensors and Actuators B: ChemicalQuantitative mass spectrometric analysis of hepatocellular carcinoma biomarker alpha-fetoprotein
2023, RSC Chemical BiologyApplication and progress of the detection technologies in hepatocellular carcinoma
2023, Genes and Diseases